Volume 27, Issue 2
February 2025
Cover image
Cover image
Scheme shown in Figure 3 from the review article by Gallus et al. “Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations” beginning on p. 352.
ISSN 1522-8517
EISSN 1523-5866
Issue navigation
Volume 27, Issue 2, February 2025
Reviews
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 319–330, https://doi.org/10.1093/neuonc/noae170
For the podcast associated with this article, please visit ‘https://soc-neuro-onc.libsyn.com/cimpact-now-update-8-grading-of-meningiomas’
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 331–337, https://doi.org/10.1093/neuonc/noae213
Potential of ex vivo organotypic slice cultures in neuro-oncology
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 338–351, https://doi.org/10.1093/neuonc/noae195
Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 352–368, https://doi.org/10.1093/neuonc/noae203
Rapid Report
Neuroimmune-competent human brain organoid model of diffuse midline glioma
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 369–382, https://doi.org/10.1093/neuonc/noae245
Basic and Translational Investigations
EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 383–397, https://doi.org/10.1093/neuonc/noae182
EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 398–414, https://doi.org/10.1093/neuonc/noae206
Brain tumoroids: Treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 415–429, https://doi.org/10.1093/neuonc/noae184
Sex differences in the molecular profile of adult diffuse glioma are shaped by IDH status and tumor microenvironment
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 430–444, https://doi.org/10.1093/neuonc/noae207
A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 445–454, https://doi.org/10.1093/neuonc/noae198
Clinical Investigations
NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 455–465, https://doi.org/10.1093/neuonc/noae171
Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 466–478, https://doi.org/10.1093/neuonc/noae183
Stereotactic radiosurgery for 1–10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 479–491, https://doi.org/10.1093/neuonc/noae201
Pediatric Neuro-Oncology
The deubiquitinase USP44 enhances cisplatin chemosensitivity through stabilizing STUB1 to promote LRPPRC degradation in neuroblastoma
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 492–507, https://doi.org/10.1093/neuonc/noae175
The Pediatric Physiatric Posterior Fossa Symptoms scale: Impairments and outcome in pediatric inpatient rehabilitation for posterior fossa brain tumors
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 508–516, https://doi.org/10.1093/neuonc/noae199
Pediatric cranial stereotactic radiosurgery: Meta-analysis and international stereotactic radiosurgery society practice guidelines
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 517–532, https://doi.org/10.1093/neuonc/noae204
Constitutional mosaicism of pathogenic variants in SMARCB1 in a subset of patients with sporadic rhabdoid tumors
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 533–544, https://doi.org/10.1093/neuonc/noae188
Neuroimaging
Dynamics of tumor evolution after Gamma Knife radiosurgery for sporadic vestibular schwannoma: Defining volumetric patterns characterizing individual trajectory
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 545–556, https://doi.org/10.1093/neuonc/noae187
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 557–566, https://doi.org/10.1093/neuonc/noae205
For the podcast associated with this article, please visit ‘https://soc-neuro-onc.libsyn.com/residual-tumor-volume-and-survival-after-ccnutmz-in-gbm’
Imaging PD-L1 in the brain—Journey from the lab to the clinic
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 567–582, https://doi.org/10.1093/neuonc/noae190
Letters to the Editor
The inconsistent terminology for the extent of resection in glioblastoma: A systematic review on 6 decades of neuro-oncological studies
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 583–585, https://doi.org/10.1093/neuonc/noae254
Inhibiting glioblastoma stem cells by targeting pyruvate carboxylase: a novel therapeutic strategy with both opportunities and challenges
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 586–588, https://doi.org/10.1093/neuonc/noae249
Reply to Letter
Inhibiting glioblastoma stem cells by targeting pyruvate carboxylase: A novel therapeutic strategy with both opportunities and challenges
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 589–590, https://doi.org/10.1093/neuonc/noae250
Society News
Society News: Forthcoming Meetings
Neuro-Oncology, Volume 27, Issue 2, February 2025, Page 591, https://doi.org/10.1093/neuonc/noae273
